A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection
Despite the success of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, there remains a clear need for new classes of preventatives for respiratory viral infections due to vaccine hesitancy, lack of sterilizing immunity, and for at‐risk patient populations, including the immunocompromised. While many neutralizing antibodies have been identified, and several approved, to treat COVID‐19, systemic delivery, large doses, and high costs have the potential to limit their widespread use, especially in low‐ and middle‐income countries. To use these antibodies more efficiently, an inhalable formulation is developed that allows for the expression of mRNA‐encoded, membrane‐anchored neutralizing antibodies in the lung to mitigate SARS‐CoV‐2 infections. First, the ability of mRNA‐encoded, membrane‐anchored, anti‐SARS‐CoV‐2 antibodies to prevent infections in vitro is demonstrated. Next, it is demonstrated that nebulizer‐based delivery of these mRNA‐expressed neutralizing antibodies potently abrogates disease in the hamster model. Overall, these results support the use of nebulizer‐based mRNA expression of neutralizing antibodies as a new paradigm for mitigating respiratory virus infections.
Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection
Despite the success of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, there remains a clear need for new classes of preventatives for respiratory viral infections due to vaccine hesitancy, lack of sterilizing immunity, and for at‐risk patient populations, including the immunocompromised. While many neutralizing antibodies have been identified, and several approved, to treat COVID‐19, systemic delivery, large doses, and high costs have the potential to limit their widespread use, especially in low‐ and middle‐income countries. To use these antibodies more efficiently, an inhalable formulation is developed that allows for the expression of mRNA‐encoded, membrane‐anchored neutralizing antibodies in the lung to mitigate SARS‐CoV‐2 infections. First, the ability of mRNA‐encoded, membrane‐anchored, anti‐SARS‐CoV‐2 antibodies to prevent infections in vitro is demonstrated. Next, it is demonstrated that nebulizer‐based delivery of these mRNA‐expressed neutralizing antibodies potently abrogates disease in the hamster model. Overall, these results support the use of nebulizer‐based mRNA expression of neutralizing antibodies as a new paradigm for mitigating respiratory virus infections.
Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection
Vanover, Daryll (author) / Zurla, Chiara (author) / Peck, Hannah E. (author) / Orr‐Burks, Nichole (author) / Joo, Jae Yeon (author) / Murray, Jackelyn (author) / Holladay, Nathan (author) / Hobbs, Ryan A. (author) / Jung, Younghun (author) / Chaves, Lorena C. S. (author)
Advanced Science ; 9
2022-12-01
13 pages
Article (Journal)
Electronic Resource
English
T‐Cell‐Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS‐CoV‐2 Infection
| Wiley | 2025
A Susceptible Cell‐Selective Delivery (SCSD) of mRNA‐Encoded Cas13d Against Influenza Infection
| Wiley | 2025
A Susceptible Cell‐Selective Delivery (SCSD) of mRNA‐Encoded Cas13d Against Influenza Infection
| Wiley | 2025
Nebulized spray deposition of PLT thin film
| British Library Online Contents | 1999
Infection Control: Does Your Program Protect You?
| British Library Online Contents | 2003